Q-omics provides the consensus-scored ZDHHC24 profile across patient tissues and cancer cell-line models. ZDHHC24 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, ZDHHC24 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, ZDHHC24 RNA expression shows 18,981 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight STAD, HNSC, and ACC as cancer lineages where ZDHHC24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZDHHC24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZDHHC24 survival associations across molecular data types. ZDHHC24 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZDHHC24 RNA expression–survival associations across cancer types. High ZDHHC24 expression shows unfavorable associations in UVM, KICH and LGG, but favorable associations in STAD, UCEC and SCLC. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for ZDHHC24 RNA expression.
This table summarizes ZDHHC24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZDHHC24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZDHHC24 shows higher tumor expression in HNSC, BLCA, STAD, LIHC, COAD and KIRP. The HNSC box plot shows higher ZDHHC24 RNA expression in tumor versus normal tissue (log2 FC = +1.063, t-test p < 0.001).
This table shows molecular features associated with ZDHHC24 in patient tissues and cancer cell lines. In patient samples, ZDHHC24 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZDHHC24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
